Introduction There have been reports of clinically relevant uterine bleeding events among
women of reproductive age exposed to rivaroxaban. Objective The aim of this study was to …

Background Antithrombotic therapies are associated with an increased bleeding risk.
Abnormal uterine bleeding data have been reported in clinical trials of patients with venous …

Direct oral anticoagulants (DOACs) apixaban and rivaroxaban have been endorsed by
clinical practice guidelines for the outpatient treatment of venous thromboembolism (VTE) …

Up to two-thirds of menstruating women experience abnormal uterine bleeding (AUB) when
treated with oral anticoagulants. However, the true prevalence of AUB for specific agents …

Introduction Rivaroxaban is a convenient oral anticoagulant for patients with venous
thromboembolism (VTE). The impact of rivaroxaban and vitamin K antagonists (VKAs) on …

Women receiving vitamin K antagonists (VKAs) require adequate contraception because of
the potential for fetal complications. It is unknown whether the use of hormonal therapy …

Essentials• Factor Xa inhibitors cause more abnormal menstrual bleeding (AUB) than
vitamin‐K antagonists (VKA).• We analyzed data of AUB in women, evaluating dabigatran …

Abstract Introduction: While Direct Oral Anticoagulants (DOACs) have been shown to have
an overall equal efficacy as and better safety profile than warfarin in patients with acute …

Background Observational data and results from post-hoc analyses in clinical trials suggest
that direct oral factor Xa inhibitors might increase menstrual bleeding intensity in women of …

Background New oral anticoagulants are increasingly used in women of childbearing age,
but apart from one case report there is no published experience with rivaroxaban exposure …